Literature DB >> 17874485

Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.

Piotr M Czaykowski1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17874485      PMCID： PMC2657971          DOI： 10.1155/2007/259752

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN： 0835-7900            Impact factor:   3.522


× No keyword cloud information.
  11 in total

1.  Downstaging or downsizing: time for a new staging system in advanced colorectal cancer?

Authors:  Graeme Poston; Rene Adam; Jean-Nicolas Vauthey
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

2.  How should we pay the piper when he's calling the tune? On the long-term affordability of cancer care in the United States.

Authors:  Scott D Ramsey
Journal:  J Clin Oncol       Date:  2007-01-10       Impact factor: 44.544

3.  Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis.

Authors:  Sigmar Stelzner; Gunter Hellmich; Rainer Koch; Klaus Ludwig
Journal:  J Surg Oncol       Date:  2005-03-15       Impact factor: 3.454

4.  Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases.

Authors:  Y J Park; K J Park; J G Park; K U Lee; K J Choe; J P Kim
Journal:  World J Surg       Date:  1999-07       Impact factor: 3.352

5.  Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.

Authors:  Adam C Berger; Elin R Sigurdson; Thomas LeVoyer; Alexandra Hanlon; Robert J Mayer; John S Macdonald; Paul J Catalano; Daniel G Haller
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

6.  FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Authors:  Christophe Tournigand; Thierry André; Emmanuel Achille; Gérard Lledo; Michel Flesh; Dominique Mery-Mignard; Emmanuel Quinaux; Corinne Couteau; Marc Buyse; Gérard Ganem; Bruno Landi; Philippe Colin; Christophe Louvet; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

7.  Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.

Authors:  T E Le Voyer; E R Sigurdson; A L Hanlon; R J Mayer; J S Macdonald; P J Catalano; D G Haller
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

8.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

9.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.